Evidence map›Paper›PMID 41247476›Full record

Observational studyGraefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie2026

Characterization of subretinal hyperreflective material and short-term visual acuity in patients with neovascular age related macular degeneration after loading dose with antiangiogenics.

Willy Carpio Rosso, Usha Chakravarthy, Said Eduardo Meneses Girado, Shirley Rosenstiehl, Tunde Peto, Francisco J Rodriguez

Abstract readObservational Study
PubMed Publisher
In one paragraph

Observational study in Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Willy Carpio RossoFundación Oftalmológica Nacional - Escuela de medicina y ciencias de la salud - Universidad del Rosario, Calle 50 N° 13-50. Bogotá, Bogota, 110221, Colombia.
Usha ChakravarthyQueen´s University Belfast , Belfast, Northern Ireland.
Said Eduardo Meneses GiradoFundación Oftalmológica Nacional - Escuela de medicina y ciencias de la salud - Universidad del Rosario, Calle 50 N° 13-50. Bogotá, Bogota, 110221, Colombia. said_menesesg@hotmail.com.ORCID http://orcid.org/0009-0007-8636-6298
Shirley RosenstiehlFundación Oftalmológica Nacional - Escuela de medicina y ciencias de la salud - Universidad del Rosario, Calle 50 N° 13-50. Bogotá, Bogota, 110221, Colombia.
Tunde PetoQueen´s University Belfast , Belfast, Northern Ireland.
Francisco J RodriguezFundación Oftalmológica Nacional - Escuela de medicina y ciencias de la salud - Universidad del Rosario, Calle 50 N° 13-50. Bogotá, Bogota, 110221, Colombia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeThis study analyzes the morphological characteristics of subretinal hyperreflective material (SHRM) and its relationship with short-term visual outcomes in patients with neovascular age-related macular degeneration (nAMD) treated with anti-vascular endothelial grown factor (anti-VEGF) at the Fundación Oftalmológica Nacional between 2011 and 2017. METHODOLOGY: An analytical observational study was conducted on 65 treatment-naïve nAMD patients who initiated treatment between January 2011 and December 2017. Spectral-Domain Optical Coherence Tomography (SD-OCT) was graded to determine quantitative and qualitative SHRM characteristics. SHRM features and best corrected visual acuity (BCVA) were correlated before and after treatment, and associations between SHRM characteristics and BCVA improvement after the loading phase were analyzed.

resultsThe median age was 75.5 years (range 68-84), and 56.9% were women. Aflibercept was the most widely used anti-VEGF (40%). Median BCVA improved from 0.8 logMAR (range 0.5-1.2) to 0.7 logMAR (range 0.4-1) after treatment. At baseline, a significant correlation was found between worse BCVA and SHRM horizontal extension (r=0.7, p=0.001), low reflectivity (p=0.017), and undefined margins (p=0.037). SHRM characteristics associated with BCVA improvement after treatment included low reflectivity (p=0.048), non-homogeneity (p=0.048), smaller width (p=0.043), and the presence of the external limiting membrane (ELM) (p=0.002) and ellipsoid zone (EZ) (p=0.017).

conclusionSHRM features such as low reflectivity, non-homogeneity, reduced width, and the presence of ELM/EZ were associated with improved short-term visual outcomes. These findings provide insight into favorable short-term SHRM characteristics, which may help establish early treatment criteria and support its role as a prognostic biomarker. KEY MESSAGES: WHAT IS KNOWN : Neovascular age-related macular degeneration (nAMD) is a progressive disease that severely impacts vision if untreated. Subretinal hyperreflective material (SHRM) is a recognized biomarker on spectral-domain optical coherence tomography (SD-OCT) and has been studied as a predictor of long-term visual outcomes in patients treated with anti-VEGF therapy. WHAT IS NEW: This study evaluates SHRM characteristics and their relationship with short-term visual outcomes after the loading dose of anti-VEGF treatment.SHRM features such as low reflectivity, undefined borders, smaller horizontal extent, and the presence of external limiting membrane (ELM) and ellipsoid zone (EZ) are associated with early visual improvement. SHRM features such as low reflectivity, undefined borders, smaller horizontal extent, and the presence of external limiting membrane (ELM) and ellipsoid zone (EZ) are associated with early visual improvement. These findings suggest that SHRM morphology could serve as an early prognostic biomarker, potentially guiding treatment decisions for better visual outcomes.

Indexed as

Angiogenesis InhibitorsRanibizumabRetinaVisual AcuityWet Macular DegenerationAgedAged, 80 and overBevacizumabDose-Response Relationship, DrugFemaleFluorescein AngiographyFollow-Up StudiesFundus OculiHumansIntravitreal InjectionsMaleafliberceptAngiogenesis InhibitorsBevacizumabRanibizumabReceptors, Vascular Endothelial Growth FactorRecombinant Fusion ProteinsVascular Endothelial Growth Factor AAge-related macular degenerationBiomarkersNeovascularizationOptical coherence tomographySubretinal hyperreflective material

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.